IP Library Granted Patent US 9,730,966
Granted Patent B2
US 9,730,966 · App. 14/968,183 · Granted Aug 15, 2017

Method of reducing appetite in a human subject comprising administering krill oil composition

Inventors: Inge Bruheim (Volda, NO); Snorre Tilseth (Bergen, NO); Jeffery Cohn (Sydney, AU); Mikko Griinari (Espoo, FI); Sebastiano Banni (Calgliari, IT); Daniele Mancinelli (Orsta, NO); Nils Hoem (Oslo, NO); Hogne Vik (Eiksmarka, NO)
Assignee: AKER BIOMARINE ANTARTIC AS
A61K35/612A61K31/202A61K31/215A61K31/683
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,730,966
App. No.
14/968,183
Granted
Aug 15, 2017
Kind
B2
Abstract

This invention discloses methods of using krill oil and compositions comprising krill oil to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. The present invention also relates to methods of using compositions comprising krill oil to modulate biological processes selected from the group consisting of glucose metabolism, lipid biosynthesis, fatty acid metabolism, cholesterol biosynthesis, and the mitochondria respiratory chain. The present invention further includes pharmaceutical and/or nutraceutical formulations made from krill oil, methods of making such formulations, and methods of administering them to treat risk factors for metabolic, cardiovascular, and inflammatory disorders. Further, a method of reducing appetite in humans by administering a krill oil composition is also disclosed.

Claims (5)

1. A method of reducing appetite in a human subject in need thereof comprising:

administering to the human subject an effective amount of a krill oil composition, said krill oil composition comprising from about 40% w/w to about 60% w/w total phospholipids, wherein said total phospholipids comprise from about 3% to about 15% ether phospholipids, and said administering is carried out under conditions to reduce the appetite of the human subject.

2. The method of claim 1 , wherein the human subject is obese.

3. The method of claim 1 , wherein the krill oil composition further comprises greater than about 100 mg/kg astaxanthin esters.

4. The method of claim 1 , wherein the krill oil composition further comprises from about 20% to 35% omega-3 fatty acids as a percentage of total fatty acids in the composition.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2024
From: AKER BIOMARINE ANTARCTIC AS
To: AKER BIOMARINE HUMAN INGREDIENTS AS
Reel/Frame 066703/0864 →
CHANGE OF NAME Recorded Dec 28, 2015
From: AKER BIOMARINE AS
To: AKER BIOMARINE ANTARCTIC AS
Reel/Frame 037364/0419 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2015
From: BRUHEIM, INGE; TILSETH, SNORRE; COHN, JEFFERY; GRIINARI, MIKKO; BANNI, SEBASTIANO; MANCINELLI, DANIELE; HOEM, NILS; VIK, HOGNE
To: AKER BIOMARINE AS
Reel/Frame 037340/0064 →
Continuity (9)
Division 14244532 · Apr 3, 2014
Division 12790575 · May 28, 2010
Continuation In Part 12057775 · Mar 28, 2008
Provisional Application 60975058 · Sep 25, 2007
Provisional Application 60983446 · Oct 29, 2007
Provisional Application 61024072 · Jan 28, 2008
Provisional Application 61181743 · May 28, 2009
Provisional Application 60920483 · Mar 28, 2007
Related Publication 20160095888A1 · Apr 7, 2016